Co-infection with hepatitis B does not alter treatment response in chronic hepatitis C

Basit Öğe Kaydı
dc.contributor.authorUyanıkoğlu, Ahmet
dc.contributor.authorAkyüz, Filiz
dc.contributor.authorBaran, Bülent
dc.contributor.authorŞimşek, Binnur Pınarbaşı
dc.contributor.authorErmiş, Fatih
dc.contributor.authorDemir, Kadir
dc.contributor.authorKaymakoğlu, Sabahattin
dc.date.accessioned2020-04-30T22:40:58Z
dc.date.available2020-04-30T22:40:58Z
dc.date.issued2013
dc.departmentDÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.descriptionUyanikoglu, Ahmet/0000-0003-4881-5244; Baran, Bulent/0000-0001-7966-2346en_US
dc.descriptionWOS: 000326273700014en_US
dc.descriptionPubMed: 23665172en_US
dc.description.abstractBackground/Aim: To investigate the clinical features and treatment response in patients with hepatitis B (HBV) and hepatitis C virus (HCV) co-infection receiving anti-HCV therapy. Patients and method: Patients with HBV/HCV co-infection, who were eligible for anti-HCV therapy, were included in the study. Patients had detectable HBsAg for at least 6 months and detectable HCV-RNA before the initiation of therapy. Primary end-point was the proportion of patients achieving sustained virological response (SVR). HBV serology and HBV-DNA results obtained during the follow-up were assessed to determine HBV clearance or reactivation after anti-HCV therapy. Results: There were 612 patients in the HCV cohort and 52 (8.5%) of them were HBV/HCV co-infected. Twenty-eight patients (20 male, mean age: 47 +/- 12) received anti-HCV treatment and followed-up for a mean duration of 53 months (12-156). Fifteen patients received peginterferon/ ribavirin combination while the remaining patients received standard interferon/ribavirin combination (n = 6) or standard interferon monotherapy (n = 7). Patients receiving interferon monotherapy were under chronic hemodialysis therapy. SVR was achieved in 14 (50%) patients at the end of follow-up. The proportion of patients with SVR in three treatment arms were not significantly different (P = 0.78). Eight of 11 patients with detectable HBV-DNA cleared HBV-DNA during treatment. Seven (25%) patients experienced a rebound in HBV-DNA, and one patient experienced an acute hepatitis flare which was controlled by tenofovir therapy. Two (7%) patients cleared HBsAg and one of them was seroconverted to anti-HBs. Conclusion: Co-infection with HBV does not have a negative impact on the efficacy of anti-HCV treatment, but HBV-DNA should be monitored to overcome the risk of HBV exacerbation. (C) 2013 Published by Elsevier Masson SAS.en_US
dc.identifier.doi10.1016/j.clinre.2013.03.002en_US
dc.identifier.endpage490en_US
dc.identifier.issn2210-7401
dc.identifier.issn2210-741X
dc.identifier.issue5en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage485en_US
dc.identifier.urihttps://doi.org/10.1016/j.clinre.2013.03.002
dc.identifier.urihttps://hdl.handle.net/20.500.12684/3097
dc.identifier.volume37en_US
dc.identifier.wosWOS:000326273700014en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherElsevier Masson, Corporation Officeen_US
dc.relation.ispartofClinics And Research In Hepatology And Gastroenterologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleCo-infection with hepatitis B does not alter treatment response in chronic hepatitis Cen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
3097.pdf
Boyut:
275.25 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu